Galectin Therapeutics (GALT) Total Liabilities (2010 - 2026)
Galectin Therapeutics (GALT) posted quarterly Total Liabilities of $146.0 million for Q1 2026, up 19.88% year-over-year from $121.8 million in Q1 2025, and little changed quarter-over-quarter from $145.7 million in Q4 2025.
Galectin Therapeutics (GALT) Total Liabilities (2010 - 2026) Analysis & Trends
Galectin Therapeutics' Total Liabilities history runs 17 years deep, the most recent figure standing at $146.0 million for Q1 2026.
- In Q1 2026, Total Liabilities rose 19.88% year-over-year to $146.0 million; the TTM figure through Mar 2026 stood at $146.0 million (up 19.88% YoY), while the FY2025 annual figure was $145.7 million, up 20.87% from the prior year.
- Total Liabilities for Q1 2026 stood at $146.0 million, roughly flat from $145.7 million in the prior quarter.
- The five-year high for Total Liabilities was $146.0 million in Q1 2026, with the low at $39.8 million in Q1 2022.
- The 5-year median for Total Liabilities is $97.0 million (2024), against an average of $94.2 million.
- The sharpest annual moves came in 2022 and 2025: Total Liabilities jumped 753.7% in 2022, then grew 12.34% in 2025.
- Galectin Therapeutics' Total Liabilities stood at $53.5 million in 2022, then jumped by 65.38% to $88.4 million in 2023, then soared by 36.32% to $120.6 million in 2024, then grew by 20.87% to $145.7 million in 2025, then rose by 0.18% to $146.0 million in 2026.
- Business Quant data shows GALT's Total Liabilities at $146.0 million in Q1 2026, $145.7 million in Q4 2025, and $136.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Galectin Therapeutics | 226.55 Mn | 226.55 Mn | - | 146.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 146.00 Mn |
| Dec 31, 2025 | 145.73 Mn |
| Sep 30, 2025 | 136.45 Mn |
| Jun 30, 2025 | 132.77 Mn |
| Mar 31, 2025 | 121.79 Mn |
| Dec 31, 2024 | 120.57 Mn |
| Sep 30, 2024 | 121.45 Mn |
| Jun 30, 2024 | 109.80 Mn |
| Mar 31, 2024 | 96.98 Mn |
| Dec 31, 2023 | 88.44 Mn |
| Sep 30, 2023 | 73.04 Mn |
| Jun 30, 2023 | 71.21 Mn |
| Mar 31, 2023 | 62.87 Mn |
| Dec 31, 2022 | 53.48 Mn |
| Sep 30, 2022 | 40.25 Mn |
| Jun 30, 2022 | 41.11 Mn |
| Mar 31, 2022 | 39.81 Mn |
| Dec 31, 2021 | 39.21 Mn |
| Sep 30, 2021 | 28.79 Mn |
| Jun 30, 2021 | 16.29 Mn |